Insider Buying: GSK (LON:GSK) Insider Purchases £29,865 in Stock

GSK plc (LON:GSK) insider Jonathan Symonds purchased 1,650 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was bought at an average cost of GBX 1,810 per share, for a total transaction of £29,865.

GSK Stock Performance

LON GSK opened at GBX 1,805.50 on Thursday. The company has a market capitalization of £72.90 billion, a PE ratio of 13.58, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. GSK plc has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 1,853.50. The company has a 50-day simple moving average of GBX 1,768.98 and a 200 day simple moving average of GBX 1,571.24.

GSK (LON:GSK) last released its earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, research analysts predict that GSK plc will post 175.980975 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on GSK shares. Jefferies Financial Group boosted their price objective on GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a research note on Monday, November 3rd. JPMorgan Chase & Co. upped their price target on shares of GSK from GBX 1,400 to GBX 1,500 and gave the company an “underweight” rating in a research note on Friday, November 7th. Berenberg Bank lifted their price target on GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research report on Monday, November 24th. Finally, Shore Capital restated a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a research note on Monday, October 20th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of GBX 1,762.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.